Cloverleaf Bio is an early-stage therapeutics company that is developing a new class of engineered tRNA therapeutics. Our tRNAs target an underappreciated vulnerability of cancer: addiction to high levels of tRNA modifying enzymes. Cloverleaf’s approach to drugging tRNA modifying enzymes uses engineered “trojan horse” tRNAs to modulate translation in cancerous cells. The programmability, potency, and specificity of our tRNAs gives us the potential to dramatically improve cancer treatment.